Community 365 Roundtable Meeting on Metastatic Cancer

The Community 365 Roundtable Meeting on the topic of Metastatic Cancer took place on Wednesday 27 October from 10:00-12:30 CEST


This meeting brought together leading policy-makers, politicians, oncology experts and patient advocates to discuss the implementation of Europe’s Beating Cancer Plan and Cancer Mission, as well as other EU policy developments relating to metastatic cancer.

27 October 2021 10:00 - 12:30 CEST

Virtual Meeting

 
  • View the Recording from the Roundtable meeting here
  • Read the Roundtable Report here.
  • Download the Roundtable meeting presentation slides here.

The Roundtable provided the opportunity to present the results of a survey of healthcare professionals in Europe and the United States, focused on unmet needs of Non-Small Cell Lung Cancer (NSCLC) patients with brain metastases. In addition, it investigated key policy needs to improve the quality of care provided to patients with metastatic cancer, and also reviewed technological and practice developments with references to the examples of breast, prostate and lung cancer. 

 

Programme

10:00-10:10 Welcome and Introduction  

Roundtable Co-Chairs:
  • Matti Aapro, President, European Cancer Organisation
  • Kathy Oliver, Co-Chair, Patient Advisory Committee, European Cancer Organisation, and Chair & founding Co-Director, The International Brain Tumour Alliance (IBTA) 
10:10-10:35 Survey results: Unmet needs of Non-Small Cell Lung Cancer (NSCLC) Patients with Brain Metastases

Session Co-Chairs:
  • Kathy Oliver, Co-Chair, Patient Advisory Committee, European Cancer Organisation, and Chair & founding Co-Director, The International Brain Tumour Alliance (IBTA)
  • Hampton Shaddock, Head, Global Affairs, Oncology, Sanofi Genzyme

This session will release and discuss key results from a survey of healthcare professionals in Europe and United States, focused on unmet needs of Non-Small Cell Lung Cancer (NSCLC) patients with brain metastases. This survey is conducted in coordination with the European Cancer Organisation; it draws on healthcare professionals’ experience to both treat these patients and understand their needs, addressing matters such as:

  • Symptoms faced by NSCLC patients with brain metastases, and infrastructures available to address them.
  • Quality of life issues faced by NSCLC patients with brain metastases and their caregivers, and support services required to tackle them.
  • Gaps in the information available to NSCLC patients with brain metastases and their caregivers, and means to achieve progress, including through the role of patient organisations.
With contributions from:
  • Jemma Reast, Research Manager and Advocate for Patient Voices, Ipsos
  • Csaba L. Dégi, Co-Chair, Survivorship and Quality of Life Network, European Cancer Organisation, and Director, International Psycho-Oncology Society (IPOS)

Read the Press Release here.
Download the Survey Report here

10:35-11:00 Metastatic Lung Cancer 

Session Co-Chairs:
  • Rudolf Huber, Past-Chair, Lung Cancer Group, Thoracic Oncology Assembly, European Respiratory Society (ERS)
  • Klaus Feldmann, Vice President and Head of Marketing Oncology, Europe and Canada, MSD

This session will allow for a multi-stakeholder exchange on current challenges and opportunities in the metastatic lung cancer field in general. Results from a recent research project on lung cancer treatment rates discrepancies across Europe will be presented; emphasis will also be put on specific features of metastatic lung cancer, such as late diagnosis, high burden of symptoms, and need for accurate tumour subtyping for adequate treatment.

With contributions from:
  • Thomas Hofmarcher, Health Economist, Swedish Institute for Health Economics (IHE)
  • Anne-Marie Baird, Member, Patient Advisory Committee, European Cancer Organisation, and President, Lung Cancer Europe
11:00-11:25 Potential of Biomarkers and Testing to Achieve Improvement in Metastatic Cancer

Session Co-Chairs:
  • Aleš Ryška, President, European Society of Pathology (ESP)
  • Rodney Berzoini Smith, Head, Oncology Medical Affairs Europe, Daiichi Sankyo

Based on interventions from key experts in the field, this session will examine the requirements to exploit the full potential of biomarkers and testing for improvement in metastatic cancer. In the context of relevant EU policy initiatives such as the establishment of a Cancer Inequalities Registry, there will be a particular focus on inequalities in access to, and quality of, biomarkers and testing in metastatic cancer across Europe, as well as on needs to better education and patient information in this respect.

With contributions from:
  • Zorana Maravic, Acting CEO, Digestive Cancers Europe (DiCE)
  • Patrick Michl, European Pancreatic Club (EPC), and Chair, Gastroenterology (W3), Martin Luther University Halle-Wittenberg
11:25-11:50 Metastatic Breast Cancer 

Session Co-Chairs:
  • Matti Aapro, President, European Cancer Organisation
  • Fatima Cardoso, President, ABC Global Alliance, and Director, Breast Unit, Champalimaud Clinical Center

With the involvement of leading specialists, policymakers and other stakeholders, this session will outline successful consensus-building and policy initiatives in the metastatic breast cancer field, as well as ongoing needs for their further support and strengthening to achieve improved outcomes for affected women. There will be a particular focus on requirements for better data, better treatments and better quality of life support in metastatic breast cancer.

With contributions from:
  • Isabelle Soerjomataram, Deputy Branch Head, Cancer Surveillance, International Agency for Research on Cancer (IARC)
  • Olivia Pagani, Breast Cancer Programme Coordinator, European School of Oncology (ESO), and Breast Cancer Consultant, Hopital Riviera-Chablais, Rennaz, Vaud
  • Tanja Spanic, President, Europa Donna
11:50-12:15 Metastatic Prostate Cancer

Session Co-Chairs:
  • Arnulf Stenzl, Adjunct Secretary General, European Association of Urology (EAU), and Board Member, European Cancer Organisation
  • Andrew Cavey, Global Program Head, Prostate Cancer, Novartis

In the context of the dramatic impact of Covid-19 on cancer across Europe, this session will feature a high-level dialogue with healthcare professionals, patients and other stakeholders on challenges posed to men’s health and in particular to metastatic prostate cancer patients. The crucial importance of multidisciplinary cancer care and the central role of nurses will be emphasised, as well as the need for better pan-European data in prostate cancer.

With contributions from:
  • Hendrique Reinders-Huisman, Urology Nurse Practitioner, Groningen, the Netherlands, and Scientific Congress Office Member, European Association of Urology Nurses (EAUN)
  • Ken Mastris, President, European Cancer Patient Coalition (ECPC), and Past-Chairman, Europa Uomo
12:15-12:30 Open Discussion 

Roundtable Co-Chairs:
  • Matti Aapro, President, European Cancer Organisation
  • Kathy Oliver, Co-Chair, Patient Advisory Committee, European Cancer Organisation, and Chair & founding Co-Director, The International Brain Tumour Alliance (IBTA) 

 

 

Speakers

  • Fatima Cardoso President, ABC Global Alliance, Director, Breast Unit, Champalimaud Clinical Center
  • Jemma Reast Research Manager and Advocate for Patient Voices, Ipsos
  • Isabelle Soerjomataram Deputy Branch Head, Cancer Surveillance, International Agency for Research on Cancer (IARC)
  • Thomas Hofmarcher Health Economist, Swedish Institute for Health Economics (IHE)
  • Arnulf Stenzl Adjunct Secretary General, European Association of Urology (EAU) and Board Member, European Cancer Organisation
  • Csaba L. Dégi Co-Chair, Survivorship and Quality of Life Network, European Cancer Organisation, and Director, International Psycho-Oncology Society (IPOS)

Speakers

  • Fatima Cardoso President, ABC Global Alliance, Director, Breast Unit, Champalimaud Clinical Center
  • Jemma Reast Research Manager and Advocate for Patient Voices, Ipsos
  • Isabelle Soerjomataram Deputy Branch Head, Cancer Surveillance, International Agency for Research on Cancer (IARC)
  • Thomas Hofmarcher Health Economist, Swedish Institute for Health Economics (IHE)
  • Arnulf Stenzl Adjunct Secretary General, European Association of Urology (EAU) and Board Member, European Cancer Organisation
  • Csaba L. Dégi Co-Chair, Survivorship and Quality of Life Network, European Cancer Organisation, and Director, International Psycho-Oncology Society (IPOS)
  • Fatima Cardoso President, ABC Global Alliance, Director, Breast Unit, Champalimaud Clinical Center Read Bio
  • Jemma Reast Research Manager and Advocate for Patient Voices, Ipsos Read Bio
  • Isabelle Soerjomataram Deputy Branch Head, Cancer Surveillance, International Agency for Research on Cancer (IARC)
  • Thomas Hofmarcher Health Economist, Swedish Institute for Health Economics (IHE) Read Bio
  • Arnulf Stenzl Adjunct Secretary General, European Association of Urology (EAU) and Board Member, European Cancer Organisation Read Bio
  • Csaba L. Dégi Co-Chair, Survivorship and Quality of Life Network, European Cancer Organisation, and Director, International Psycho-Oncology Society (IPOS) Read Bio
  • Rudolf Huber Past-Chair, Lung Cancer Group, Thoracic Oncology Assembly, European Respiratory Society (ERS) Read Bio
  • Aleš Ryška President, European Society of Pathology (ESP) Read Bio
  • Ken Mastris President, European Cancer Patient Coalition (ECPC) and Past-Chairman, Europa Uomo Read Bio
  • Anne-Marie Baird Member, Patient Advisory Committee, European Cancer Organisation, and President, Lung Cancer Europe Read Bio
  • Tanja Spanic President, Europa Donna Read Bio
  • Zorana Maravic Acting CEO, Digestive Cancers Europe (DiCE) Read Bio
  • Patrick Michl European Pancreatic Club (EPC), and Chair, Gastroenterology (W3), Martin Luther University Halle-Wittenberg Read Bio
  • Olivia Pagani Breast Cancer Programme Coordinator, European School of Oncology (ESO), and Breast Cancer Consultant, Hopital Riviera-Chablais, Rennaz, Vaud Read Bio
  • Hendrique Reinders-Huisman Urology Nurse Practitioner, Groningen, the Netherlands, and Scientific Congress Office Member, European Association of Urology Nurses (EAUN) Read Bio
  • Hampton Shaddock Head, Global Affairs, Oncology, Sanofi Genzyme
  • Klaus Feldmann Vice President and Head of Marketing Oncology, Europe and Canada, MSD Read Bio
  • Rodney Berzoini Smith Head, Oncology Medical Affairs Europe, Daiichi Sankyo Read Bio
  • Andrew Cavey Global Program Head, Prostate Cancer, Novartis Read Bio
  • Matti Aapro President, European Cancer Organisation Read Bio
  • Kathy Oliver Co-Chair, Patient Advisory Committee, European Cancer Organisation, and Chair & founding Co-Director, The International Brain Tumour Alliance (IBTA) 

Speakers

  • Fatima Cardoso President, ABC Global Alliance, Director, Breast Unit, Champalimaud Clinical Center
  • Jemma Reast Research Manager and Advocate for Patient Voices, Ipsos
  • Isabelle Soerjomataram Deputy Branch Head, Cancer Surveillance, International Agency for Research on Cancer (IARC)
  • Thomas Hofmarcher Health Economist, Swedish Institute for Health Economics (IHE)
  • Arnulf Stenzl Adjunct Secretary General, European Association of Urology (EAU) and Board Member, European Cancer Organisation
  • Csaba L. Dégi Co-Chair, Survivorship and Quality of Life Network, European Cancer Organisation, and Director, International Psycho-Oncology Society (IPOS)

Speakers

  • Fatima Cardoso President, ABC Global Alliance, Director, Breast Unit, Champalimaud Clinical Center
  • Jemma Reast Research Manager and Advocate for Patient Voices, Ipsos
  • Isabelle Soerjomataram Deputy Branch Head, Cancer Surveillance, International Agency for Research on Cancer (IARC)
  • Thomas Hofmarcher Health Economist, Swedish Institute for Health Economics (IHE)
  • Arnulf Stenzl Adjunct Secretary General, European Association of Urology (EAU) and Board Member, European Cancer Organisation
  • Csaba L. Dégi Co-Chair, Survivorship and Quality of Life Network, European Cancer Organisation, and Director, International Psycho-Oncology Society (IPOS)